Montelukast Teva Uk

Montelukast, the active ingredient in Montelukast Teva Uk, is a leukotriene receptor antagonist presented as a tablet for oral use. It blocks cysteinyl leukotriene receptors, helping to control airway inflammation and nasal symptoms. The medication is indicated for the treatment of asthma and allergic rhinitis in both adult and pediatric patients.

GNH USA supplies Montelukast Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Montelukast acts on the leukotriene pathway to reduce inflammation in respiratory conditions.

Asthma: improves long‑term control and reduces the frequency of exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness

Serious or Rare Side Effects: - Allergic reactions (rash, angioedema, anaphylaxis) - Neuropsychiatric events (mood changes, depression, suicidal thoughts) - Hepatic injury (elevated liver enzymes, hepatitis)

When prescribing Montelukast, clinicians should consider several safety measures.

Assess asthma control before initiating therapy: ensure patient is on appropriate baseline treatment. Monitor for neuropsychiatric symptoms: watch for mood changes or suicidal thoughts. Use with caution in patients with hepatic impairment: dose adjustment may be required. Avoid in individuals with known hypersensitivity to montelukast or any formulation components. Review concomitant medications for potential interactions, especially CYP3A4 modulators. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast plasma levels. - Concurrent use with other leukotriene pathway inhibitors (e.g., zafirlukast, zileuton): risk of additive adverse effects. - Phenobarbital or other enzyme inducers: may reduce therapeutic effect of montelukast.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may affect INR, requiring closer monitoring. - Beta‑agonists (e.g., albuterol): additive bronchodilation may occur, adjust dosing if needed. - Antidepressants or antipsychotics: potential for enhanced neuropsychiatric side effects.